Literature DB >> 17166846

Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells.

Sandra Cascio1, Viviana Bartella, Cecilia Garofalo, Antonio Russo, Antonio Giordano, Eva Surmacz.   

Abstract

Cross-talk between insulin-like growth factor 1 (IGF-1) and estrogen receptor alpha (ER) regulates gene expression in breast cancer cells, but the underlying mechanisms remain unclear. Here, we studied how 17-beta-estradiol (E2) and IGF-1 affect ER transcriptional machinery in MCF-7 cells. E2 treatment stimulated ER loading on the estrogen response element (ERE) in the pS2 promoter and on the AP-1 motif in the cyclin D1 promoter. On ERE, similar amounts of liganded ER were found at 1-24-h time points, whereas on AP-1, ER binding fluctuated over time. At 1 h, liganded ER was recruited to ERE together with histone acetyltransferases SRC-1 and p300, ubiquitin ligase E6-AP, histone methyltransferase Carm1 (Carm), and polymerase (pol) II. This coincided with increased histone H3 acetylation and up-regulation of pS2 mRNA levels. At the same time, E2 moderately increased cyclin D1 expression, which was associated with the recruitment of liganded ER, SRC-1, p300, ubiquitin ligase E6-AP (E6L), Mdm2, and pol II, but not other regulatory proteins, to AP-1. In contrast, at 1 h, IGF-1 increased the recruitment of the ER.SRC-1.p300.E6L.Mdm2.Carm.pol II complex on AP-1, but not on ERE, and induced cyclin D1, but not pS2, mRNA expression. Notably, ER knockdown reduced the association of ER, E6L, Mdm2, Carm, and pol II with AP-1 and resulted in down-regulation of cyclin D1 expression. IGF-1 potentiated the effects of E2 on ERE but not to AP-1 and increased E2-dependent pS2, but not cyclin D1, mRNA expression. In conclusion, E2 and IGF-1 differentially regulate ER transcription at ERE and AP-1 sites.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17166846     DOI: 10.1074/jbc.M606244200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Authors:  Xiaonan Hou; Fei Huang; Luciana F Macedo; Sean C Harrington; Karen A Reeves; Ann Greer; Friedrich Graf Finckenstein; Angela Brodie; Marco M Gottardis; Joan M Carboni; Paul Haluska
Journal:  Cancer Res       Date:  2011-10-31       Impact factor: 12.701

2.  Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through the oestrogen beta receptor.

Authors:  K W Leung; L W T Cheung; Y L Pon; R N S Wong; N K Mak; T-P D Fan; S C L Au; J Tombran-Tink; A S T Wong
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

3.  Cotranscriptional splicing potentiates the mRNA production from a subset of estradiol-stimulated genes.

Authors:  Danielle Bittencourt; Martin Dutertre; Gabriel Sanchez; Jérôme Barbier; Lise Gratadou; Didier Auboeuf
Journal:  Mol Cell Biol       Date:  2008-07-21       Impact factor: 4.272

4.  CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor alpha by cAMP.

Authors:  Sophie Carascossa; Peter Dudek; Bruno Cenni; Pierre-André Briand; Didier Picard
Journal:  Genes Dev       Date:  2010-04-01       Impact factor: 11.361

Review 5.  Minireview: Tipping the balance: ligand-independent activation of steroid receptors.

Authors:  Marcela A Bennesch; Didier Picard
Journal:  Mol Endocrinol       Date:  2015-01-27

6.  Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice.

Authors:  Jie Tian; Thomas R Berton; Stephanie H Shirley; Isabel Lambertz; Irma B Gimenez-Conti; John DiGiovanni; Kenneth S Korach; Claudio J Conti; Robin Fuchs-Young
Journal:  J Clin Invest       Date:  2011-12-19       Impact factor: 14.808

7.  The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.

Authors:  Marc A Becker; Yasir H Ibrahim; Xiaojiang Cui; Adrian V Lee; Douglas Yee
Journal:  Mol Endocrinol       Date:  2011-02-03

8.  Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.

Authors:  Marilena Lanzino; Diego Sisci; Catia Morelli; Cecilia Garofalo; Stefania Catalano; Ivan Casaburi; Claudia Capparelli; Cinzia Giordano; Francesca Giordano; Marcello Maggiolini; Sebastiano Andò
Journal:  Nucleic Acids Res       Date:  2010-04-26       Impact factor: 16.971

Review 9.  Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?

Authors:  Alfredo Fucito; Chiara Lucchetti; Antonio Giordano; Gaetano Romano
Journal:  Int J Biochem Cell Biol       Date:  2007-10-23       Impact factor: 5.085

10.  Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor beta.

Authors:  Nathalie Picard; Catherine Charbonneau; Mélanie Sanchez; Anne Licznar; Muriel Busson; Gwendal Lazennec; André Tremblay
Journal:  Mol Endocrinol       Date:  2007-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.